Medivir to present at the ABGSC Life Science Summit

Rhea-AI Summary

Medivir AB (Nasdaq Stockholm: MVIR) will present at the ABGSC Life Science Summit on May 25, 2021. Represented by interim CEO Magnus Christensen and Chief Scientific Officer Fredrik Öberg, the presentation will focus on Medivir's innovative cancer drug development, particularly MIV-818, designed to selectively target liver cancer. The presentation will be accessible post-seminar on Medivir's website. Medivir collaborates with partners for drug development, including the exclusive out-licensing of Birinapant to IGM Biosciences for solid tumor treatments.

STOCKHOLM, May 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will present at the virtual meeting ABGSC Life Science Summit, today, May 25. The company will be represented by Magnus Christensen, interim CEO, and Fredrik Öberg, Chief Scientific Officer.

The presentation will be available after the seminar on Medivirs website; www.medivir.com.

For additional information, please contact

Magnus Christensen, interim CEO and CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com 

Medivir in brief

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. 

Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/medivir-to-present-at-the-abgsc-life-science-summit,c3353086

The following files are available for download:

https://mb.cision.com/Main/652/3353086/1422088.pdf

Press release (PDF)

 

View original content:http://www.prnewswire.com/news-releases/medivir-to-present-at-the-abgsc-life-science-summit-301298511.html

SOURCE Medivir

FAQ

What is Medivir presenting at the ABGSC Life Science Summit?

Medivir is discussing its innovative cancer drug development, particularly focusing on MIV-818.

Who represented Medivir at the ABGSC Life Science Summit?

Magnus Christensen, interim CEO, and Fredrik Öberg, Chief Scientific Officer.

When did Medivir present at the ABGSC Life Science Summit?

Medivir presented at the summit on May 25, 2021.

Where can I find Medivir's presentation after the ABGSC Life Science Summit?

The presentation will be available on Medivir's website after the seminar.

What is MIV-818 and its significance?

MIV-818 is a pro-drug being developed to selectively treat liver cancer cells with minimized side effects.

What collaborations does Medivir have in its drug development?

Medivir collaborates with partners, including IGM Biosciences, for the development of Birinapant.